Traws Pharma(TRAW)
$0.28+0.03 (+13.60%)
TRAW
Traws Pharma financials statements
$0.28
At close:+0.03 (+13.60%)
Want to see TRAW full AI Analyst Report?
Traws Pharma (TRAW) Ratios
1,879 Followers
Traws Pharma Ratios
TRAW's free cash flow for Q2 2026 was $-2.58M. For the 2026 fiscal year, TRAW's free cash flow was increased by $0.00 and operating cash flow was $-2.58M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Dec 24 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 |
| Quick Ratio | 0.72 | 2.16 | 2.46 | 4.89 | 9.06 |
| Cash Ratio | 0.34 | 1.85 | 2.26 | 4.82 | 9.01 |
| Solvency Ratio | 0.82 | -0.97 | -1.58 | -1.71 | -1.73 |
| Operating Cash Flow Ratio | -1.63 | -2.58 | -1.94 | -2.03 | -3.19 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -3.27M | $ -31.64M | $ 10.65M | $ 28.28M | $ 46.07M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -16.88 | -0.79 | 2.13 | 1.39 | 1.20 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.21 | 0.13 | 1.03 | 1.98 | 3.34 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 94.69% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -640.68% | -73682.74% | -8981.42% | -8684.51% | -7299.12% |
| EBITDA Margin | -638.49% | -73677.43% | -8974.34% | -8678.32% | -7292.92% |
| Operating Profit Margin | -640.68% | -21835.40% | -8981.42% | -8684.51% | -7299.12% |
| Pretax Profit Margin | 328.67% | -73682.74% | -8384.07% | -8391.15% | -7151.77% |
| Net Profit Margin | 328.67% | -24192.04% | -8384.07% | -8391.15% | -7151.77% |
| Continuous Operations Profit Margin | 328.67% | -73682.74% | -8384.07% | -8391.15% | -7151.77% |
| Net Income Per EBT | 100.00% | 32.83% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | -51.30% | 337.45% | 93.35% | 96.62% | 97.98% |
| Return on Assets (ROA) | 86.37% | -219.03% | -83.53% | -48.17% | -29.13% |
| Return on Equity (ROE) | -1457.87% | 172.85% | -177.55% | -66.99% | -35.05% |
| Return on Capital Employed (ROCE) | 3379.02% | -367.47% | -150.77% | -62.65% | -33.42% |
| Return on Invested Capital (ROIC) | 3379.02% | -367.47% | -150.77% | -62.65% | -33.42% |
| Return on Tangible Assets | 113.35% | -219.03% | -83.53% | -48.17% | -29.13% |
| Earnings Yield | 98.63% | -396.54% | -120.37% | -139.54% | -37.66% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.74 | 0.13 | 12.56 | 7.79 | 8.07 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 398.57 | 22.60 | 10.27 | 9.42 | 5.95 |
| Asset Turnover | 0.26 | 0.01 | 0.01 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.54 | 0.02 | 0.01 | 0.01 | 0.01 |
| Cash Conversion Cycle | 496.35 | -246140.28 | 29.07 | 46.84 | 45.22 |
| Days of Sales Outstanding | 496.35 | 2850.55 | 29.07 | 46.84 | 45.22 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 248990.83 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 496.35 | 2850.55 | 29.07 | 46.84 | 45.22 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.21 | -19.19 | -21.36 | -19.48 | -28.94 |
| Free Cash Flow Per Share | -2.52 | -19.19 | -21.38 | -19.48 | -28.94 |
| Dividend Paid and CapEx Coverage Ratio | -7.03 | 0.00 | -1280.86 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -7.03 | 0.00 | -1280.86 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -6.52 | -131.82 | -79.35 | -72.10 | -86.23 |
| Free Cash Flow Yield | -223.39% | -216.07% | -114.00% | -119.89% | -45.40% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 1.36 | -0.25 | -0.83 | -0.72 | -2.66 |
| Price-to-Sales (P/S) Ratio | 3.33 | 61.01 | 69.65 | 60.13 | 189.92 |
| Price-to-Book (P/B) Ratio | -14.78 | -0.44 | 1.48 | 0.48 | 0.93 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.45 | -0.46 | -0.88 | -0.83 | -2.20 |
| Price-to-Operating Cash Flow Ratio | -0.51 | -0.46 | -0.88 | -0.83 | -2.20 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | -0.00 | 1.77 | 0.13 | 0.05 |
| Enterprise Value Multiple | -0.31 | 0.05 | 0.25 | 1.28 | 0.74 |
| Enterprise Value | 5.48M | -7.55M | -5.08M | -25.17M | -12.15M |
| EV to EBITDA | -0.31 | 0.05 | 0.25 | 1.28 | 0.74 |
| EV to Sales | 1.96 | -33.41 | -22.48 | -111.36 | -53.75 |
| EV to Free Cash Flow | -0.26 | 0.25 | 0.28 | 1.54 | 0.62 |
| EV to Operating Cash Flow | -0.30 | 0.25 | 0.28 | 1.54 | 0.62 |
| Tangible Book Value Per Share | -0.38 | -20.37 | 12.71 | 33.85 | 68.50 |
| Shareholders’ Equity Per Share | -0.08 | -20.37 | 12.71 | 33.85 | 68.50 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.34 | 0.15 | 0.27 | 0.27 | 0.34 |
| Net Income Per Share | 1.11 | -35.21 | -22.57 | -22.68 | -24.01 |
| Tax Burden | 1.00 | 0.33 | 1.00 | 1.00 | 1.00 |
| Interest Burden | -0.51 | 1.00 | 0.93 | 0.97 | 0.98 |
| Research & Development to Revenue | 4.35 | 576.60 | 50.58 | 50.47 | 32.29 |
| SG&A to Revenue | 3.05 | 54.38 | 40.24 | 37.38 | 41.70 |
| Stock-Based Compensation to Revenue | 0.26 | 0.00 | 5.76 | 5.19 | 2.55 |
| Income Quality | -1.98 | 0.54 | 0.95 | 0.86 | 1.21 |
Currency in USD
